Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer.
暂无分享,去创建一个
T. Ideker | G. Omenn | Matan Hofree | M. Snyder | R. Beavis | Hogune Im | F. Robertson | W. Hancock | J. Reuben | M. Cristofanilli | Y. Paik | S. Fanayan | Z. Mu | Shiaw-lin Wu | E. Zhang | A. Zhang | Seul‐Ki Jeong | Shiaw‐lin Wu
[1] F. Schmitt,et al. Expression of p 120-catenin isoforms correlates with genomic and transcriptional phenotype of breast cancer cell lines , 2014 .
[2] S. Hanash,et al. Identification of Potential Glycan Cancer Markers with Sialic Acid Attached to Sialic Acid and Up-regulated Fucosylated Galactose Structures in Epidermal Growth Factor Receptor Secreted from A431 Cell Line* , 2013, Molecular & Cellular Proteomics.
[3] William S Hancock,et al. Uniting ENCODE with genome-wide proteomics , 2012, Nature Biotechnology.
[4] S. Duffy,et al. Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. , 2012, Cancer biomarkers : section A of Disease markers.
[5] Chao Wu,et al. Integrating gene expression and protein-protein interaction network to prioritize cancer-associated genes , 2012, BMC Bioinformatics.
[6] Hugo Y. K. Lam,et al. Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.
[7] M. Laloraya,et al. CrkL is a co-activator of estrogen receptor alpha that enhances tumorigenic potential in cancer. , 2011, Molecular endocrinology.
[8] S. Hanash,et al. A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome. , 2011, Analytical chemistry.
[9] Juergen Kast,et al. In silico protein interaction analysis using the global proteome machine database. , 2011, Journal of proteome research.
[10] C. Vogel,et al. Dual HER2-targeted approaches in HER2-positive breast cancer , 2011, Breast Cancer Research and Treatment.
[11] M. Duffy,et al. The role of S100 genes in breast cancer progression , 2011, Tumor Biology.
[12] B. Garcia,et al. Proteomics , 2011, Journal of biomedicine & biotechnology.
[13] Jacob J. Kennedy,et al. The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. , 2010, Journal of chromatography. A.
[14] A. Monteiro,et al. BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines. , 2010, The American journal of pathology.
[15] Libing Song,et al. Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1 , 2009, Oncogene.
[16] S. Agelaki,et al. Caveolin-1 regulates EGFR signalling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition , 2009, Cancer biology & therapy.
[17] Dana M. Brantley-Sieders,et al. Eph receptors in breast cancer: roles in tumor promotion and tumor suppression , 2008, Breast Cancer Research.
[18] Jie Gao,et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients , 2008, BMC Cancer.
[19] Emmanuel Barillot,et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells , 2008, Breast Cancer Research.
[20] Hyungwon Choi,et al. Significance Analysis of Spectral Count Data in Label-free Shotgun Proteomics*S , 2008, Molecular & Cellular Proteomics.
[21] D. Chuderland,et al. Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration. , 2008, Experimental cell research.
[22] B. Williams,et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.
[23] Libing Song,et al. Astrocyte Elevated Gene-1 is a Novel Prognostic Marker for Breast Cancer Progression and Overall Patient Survival , 2008, Clinical Cancer Research.
[24] F. Schmitt,et al. Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival , 2008, Journal of Clinical Pathology.
[25] W. Hancock,et al. A proteomic analysis of the plasma glycoproteins of a MCF-7 mouse xenograft: a model system for the detection of tumor markers. , 2008, Journal of proteome research.
[26] J. Minna,et al. Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer Cells* , 2008, Journal of Biological Chemistry.
[27] Robin L. Jones,et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.
[28] Q. Jiang,et al. Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway , 2008, BMC Cancer.
[29] F. Schmitt,et al. Expression of p120-Catenin Isoforms Correlates with Genomic and Transcriptional Phenotype of Breast Cancer Cell Lines , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[30] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Andrew Menzies,et al. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. , 2007, Genome research.
[32] B. Deurs,et al. Activation of the EGFR Gene Target EphA2 Inhibits Epidermal Growth Factor–Induced Cancer Cell Motility , 2007, Molecular Cancer Research.
[33] Qingbo Li,et al. An unconventional pathway for reduction of CO2 to methane in CO-grown Methanosarcina acetivorans revealed by proteomics , 2006, Proceedings of the National Academy of Sciences.
[34] W. Hancock,et al. Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. , 2006, Clinical chemistry.
[35] E. Petricoin,et al. Dynamic Profiling of the Post-translational Modifications and Interaction Partners of Epidermal Growth Factor Receptor Signaling after Stimulation by Epidermal Growth Factor Using Extended Range Proteomic Analysis (ERPA)*S , 2006, Molecular & Cellular Proteomics.
[36] D. Lodygin,et al. Epigenetic silencing of 14-3-3sigma in cancer. , 2006, Seminars in Cancer Biology.
[37] J. Benítez,et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer , 2006, Breast Cancer Research and Treatment.
[38] Rosamonde E Banks,et al. Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies , 2005, Proteomics.
[39] D. Lev,et al. Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells , 2004, British Journal of Cancer.
[40] M. Sliwkowski,et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.
[41] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[42] Wen-Hsiung Li,et al. Mammalian housekeeping genes evolve more slowly than tissue-specific genes. , 2004, Molecular biology and evolution.
[43] Jaakko Astola,et al. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines , 2004, Oncogene.
[44] E. Kubista,et al. Co-Expression of ErbB-Family Members in Human Breast Cancer: Her-2/neu is the Preferred Dimerization Candidate in Nodal-positive Tumors , 2003, Breast Cancer Research and Treatment.
[45] S. Ethier. Identifying and Validating Causal Genetic Alterations in Human Breast Cancer , 2003, Breast Cancer Research and Treatment.
[46] E. Greenwood. Breast cancer: EMSY forges a link , 2004, Nature Reviews Cancer.
[47] E. Kubista,et al. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. , 2004, Breast cancer research and treatment.
[48] M. Gerstein,et al. Comparing protein abundance and mRNA expression levels on a genomic scale , 2003, Genome Biology.
[49] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[50] W. Hancock,et al. An approach to the proteomic analysis of a breast cancer cell line (SKBR‐3) , 2003, Proteomics.
[51] P. Vertino,et al. Effects of methylation on expression of TMS1/ASC in human breast cancer cells , 2003, Oncogene.
[52] J. Downward. Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.
[53] F. Maurer,et al. The ErbB 2 ErbB 3 heterodimer functions as an oncogenic unit : ErbB 2 requires ErbB 3 to drive breast tumor cell proliferation , 2003, Nature Reviews Cancer.
[54] M. Naujokas,et al. Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. , 2002, Molecular biology of the cell.
[55] O. Monni,et al. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. , 2001, Cancer research.
[56] R. Bast,et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] John Mendelsohn,et al. The EGF receptor family as targets for cancer therapy , 2000, Oncogene.
[58] T. Pandita,et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[59] O. Kallioniemi,et al. Molecular cytogenetic analysis of 11 new breast cancer cell lines , 1999, British Journal of Cancer.
[60] J. Fletcher,et al. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.
[61] D. Uchida,et al. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tryosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4 , 1997, Oncogene.
[62] P. D’Eustachio,et al. The SH2 domain protein GRB‐7 is co‐amplified, overexpressed and in a tight complex with HER2 in breast cancer. , 1994, The EMBO journal.
[63] M. Shoyab,et al. Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells. , 1993, The Journal of biological chemistry.
[64] W. Zhang,et al. The effect of antisense p120 construct on p120 expression and cell proliferation in human breast cancer MCF-7 cells. , 1993, Cancer letters.